Sterling Global Strategies’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Sterling Global Strategies’s Portfolio DMK Stock Details DMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$26K	Sell	175 -24	-12%	-$4.64K	0.14%	26
2018 Q4	$31.4K	Sell	199 -114	-36%	-$21.9K	0.16%	86
2018 Q3	$77K	Hold	313	–	–	0.33%	28
2018 Q2	$71K	Hold	313	–	–	0.46%	26
2018 Q1	$77K	Sell	313 -17	-5%	-$4.46K	0.36%	25
2017 Q4	$102K	Buy	330 +123	+59%	+$40.5K	0.43%	27
2017 Q3	$76K	Sell	207 -806	-80%	-$286K	0.31%	32
2017 Q2	$369K	Buy	1,013 +404	+66%	+$121K	1.77%	12
2017 Q1	$181K	Buy	609 +38	+7%	+$9.59K	0.88%	27
2016 Q4	$126K	Buy	571 +271	+90%	+$54.3K	0.51%	24
2016 Q3	$72K	Buy	+300	New	+$62.3K	0.27%	29

Other funds holding DMK

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return

Sterling Global Strategies's DMK Position: Q1 2019 in Review

Sterling Global Strategies reduced its DMK Pharmaceuticals Corporation Common Stock (DMK) stake by 12% in Q1 2019, selling an estimated $4.64K and leaving 175 shares worth $26K. The position accounts for 0.14% of the portfolio, ranked #26.

Sterling Global Strategies first reported a position in DMK in Q3 2016 and has held it in 11 quarters since. The position peaked at $369K in Q2 2017. 57 funds tracked by Wall St. Rank hold DMK as of Q1 2019.

Sterling Global Strategies held 175 shares of DMK Pharmaceuticals Corporation Common Stock worth $26K as of Q1 2019.
Sterling Global Strategies sold 24 DMK Pharmaceuticals Corporation Common Stock shares in Q1 2019, an estimated $4.64K.
DMK Pharmaceuticals Corporation Common Stock made up 0.14% of Sterling Global Strategies's portfolio in Q1 2019, its #26 holding.
Sterling Global Strategies first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q3 2016 and has held it in 11 quarters since.
Sterling Global Strategies's DMK Pharmaceuticals Corporation Common Stock position peaked at $369K in Q2 2017.
57 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q1 2019.

Based on Sterling Global Strategies's 13F filing for Q1 2019, filed 15 May 2019.